Articles related to CARDIOVASCULAR DISEASE (CVD)

Atorvastatin reduced major cardiovascular events among adults aged 70 years and older without known cardiovascular disease, diabetes, or dementia, but the benefit did not translate into a statistically significant improvement in disability-free survival over nearly six years of follow-up.

The FDA approved tirzepatide to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes. SURPASS-CVOT established noninferiority to dulaglutide rather than cardiovascular superiority.

Three-year increases or sustained elevations in NT-proBNP were associated with greater cardiovascular and mortality risks among older adults without prior cardiovascular disease. Participants whose elevations resolved had risks resembling those who remained free of heart stress.

A systematic review and meta-analysis found that inclisiran significantly reduced LDL cholesterol compared with placebo across diverse hyperlipidemia populations. Long-term cardiovascular outcome data remain limited despite consistent lipid-lowering efficacy and favorable safety findings.

Emerging evidence suggests the sodium-to-potassium ratio may better reflect cardiovascular risk than sodium intake alone. Experts emphasized that increasing dietary potassium alongside sodium reduction may support blood pressure control, while acknowledging important safety considerations for select patient populations.

Discontinuing statins in adults 75 years and older without prior cardiovascular disease did not increase mortality or major cardiovascular events over three years in a randomized trial. LDL cholesterol rose substantially after discontinuation, and longer-term effects remain uncertain.